Gynecologic cancers, including ovarian, endometrial, cervical, vulvar, and vaginal cancers, affect hundreds of thousands of women worldwide each year. Accurate diagnostics and early detection are key to improved outcomes.
💡By integrating novel MSI testing into daily workflows, we enable oncologists and pathologists to deliver earlier diagnoses, more targeted therapies, and better patient outcomes in gynecologic oncology.
At MSInsight, we are committed to enhancing cancer care through genomic innovation. Our MSI Care technology enables accurate detection of microsatellite instability (MSI) directly from NGS data—supporting clinicians in the identification of patients with endometrial and ovarian cancers linked to Lynch syndrome and guiding treatment decisions with increased confidence.
